Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?

Bibliography

• PERELSON AS, NEUMANN AU, MARKOWITZ M, LEONARD JM, HO DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 271(5255):1582-1586.
   PubMed Web of Science ®Google Scholar
• MARSCHNER IC, COLLIER AC, COOMBS RW et al.: Use of changes in plasma levels of human immunodeficiency virus Type 1 RNA to assess the clinical benefit of antiretroviral therapy. J. Infect. Dis. (1998) 177(1):40-47.
   PubMed Web of Science ®Google Scholar
• MELLORS JW, MUNOZ A, GIORGI JV et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. (1997) 126(12):946-954.
   PubMed Web of Science ®Google Scholar
• GULICK RM, MELLORS JW, HAVLIR D et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. (1997) 337(11):734-739.
   PubMed Web of Science ®Google Scholar
• MONTANER JS, REISS P, COOPER D et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA (1998) 279(12):930-937.
   PubMed Web of Science ®Google Scholar
• HAMMER SM, SQUIRES KE, HUGHES MD et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. (1997) 337(11):725-733.
   PubMed Web of Science ®Google Scholar
• DORSEY BD, LEVIN RB, MCDANIEL SL et al.: L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. (1994) 37(21):3443-3451.
   PubMed Web of Science ®Google Scholar
• BALANI SK, ARISON BH, MATHAI L et al.: Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. (1995) 23(2):266-270.
   PubMed Web of Science ®Google Scholar
• DEUTSCH P, TEPPLER H, SQUIRES K et al.: Antiviral activity of L-735,524, an HIV protease inhibitor in infected patients. Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, USA (1994) Abstract I59.
   Google Scholar
• STEIGBEL RT, BERRY P, MELLORS J, MAHON D: Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK 639) at escalating dose. Program and abstracts of the 4th International Conference on Retroviruses and Opportunistic Infections. Washington, DC, USA (22 – 26 January 1996). Abstract 146.
   Google Scholar
• BOYD MA, SRASUEBKUL P, KHONGPHATTANAYOTHIN M et al.: Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antivir. Ther. (2006) 11(2):223-232.
   PubMed Web of Science ®Google Scholar
• AVIHINGSANON A, KERR SJ, BOYD MA et al.: Long–term efficacy, safety, and tolerability of indinavir-based therapy in nucleoside experienced HIV-1-infected patients in a resource limited setting: 272 week follow-up of the HIV-NAT 005 study. Program and abstracts of the XVI International AIDS Conference. Toronto, Canada (13 – 18 August 2006). Abstract no. WEPE0121.
   Google Scholar
• ARNAIZ JA, MALLOLAS J, PODZAMCZER D et al.: Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS (2003) 17(6):831-840.
   PubMed Web of Science ®Google Scholar
• DRAGSTED UB, GERSTOFT J, PEDERSEN C et al.: Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus Type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis. (2003) 188(5):635-642.
   PubMed Web of Science ®Google Scholar
• BURGER D, BOYD M, DUNCOMBE C et al.: Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J. Antimicrob. Chemother. (2003) 51(5):1231-1238.
   PubMed Web of Science ®Google Scholar
• SOLAS C, BASSO S, POIZOT-MARTIN I et al.: High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J. Acquir. Immune Defic. Syndr. (2002) 29(4):374-377.
   Google Scholar
• STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. (1999) 341(25):1865-1873.
   PubMed Web of Science ®Google Scholar
• BOYD MA, SIANGPHOE U, RUXRUNGTHAM K et al.: Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Med. (2005) 6(6):410-420.
   PubMed Web of Science ®Google Scholar
• AVIHINGSANON A, BOYD MA, PORNPRASIT P et al.: Long term durability of boosted indinavir and efavirenz in patients with combination nucleoside failure in a resource constrained setting: 4-year follow-up of HIV-NAT 009. Program and abstracts of the XVI International AIDS Conference. Toronto, Canada (13 – 18 August 2006). Poster THPE0126.
   Google Scholar
• BOYD MA, AARNOUTSE RE, RUXRUNGTHAM K et al.: Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. J. Acquir. Immune Defic. Syndr. (2003) 34(2):134-139.
   Google Scholar
• ZUCKER SD, QIN X, ROUSTER SD et al.: Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl Acad. Sci. USA (2001) 98(22):12671-12676.
   Google Scholar
• BOYD MA, SRASUEBKUL P, RUXRUNGTHAM K et al.: Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet. Genomics (2006) 16(5):321-329.
   Google Scholar
• KOPP JB, MILLER KD, MICAN JA et al.: Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. (1997) 127(2):119-125.
   PubMed Web of Science ®Google Scholar
• BOUBAKER K, SUDRE P, BALLY F et al.: Changes in renal function associated with indinavir. AIDS (1998) 12(18):F249-F254.
   PubMedGoogle Scholar
• DIELEMAN JP, GYSSENS IC, VAN DER ENDE ME, DE MARIE S, BURGER DM: Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS (1999) 13(4):473-478.
   PubMed Web of Science ®Google Scholar
• BOYD MA, SIANGPHOE U, RUXRUNGTHAM K et al.: The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J. Antimicrob. Chemother. (2006) 57(6):1161-1167.
   PubMed Web of Science ®Google Scholar
• MERAVIGLIA P, ANGELI E, DEL SORBO F et al.: Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS (2002) 16(15):2089-2093.
   PubMed Web of Science ®Google Scholar
• MARTINEZ E, LEGUIZAMON M, MALLOLAS J, MIRO JM, GATELL JM: Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin. Infect. Dis. (1999) 29(2):422-425.
   PubMed Web of Science ®Google Scholar
• HSU A, GRANNEMAN GR, CAO G et al.: Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother. (1998) 42(11):2784-2791.
   PubMed Web of Science ®Google Scholar
• GHOSN J, LAMOTTE C, AIT-MOHAND H et al.: Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS (2003) 17(2):209-214.
   PubMed Web of Science ®Google Scholar
• DUVIVIER C, MYRTO A, MARCELIN AG et al.: Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antivir. Ther. (2003) 8(6):603-609.
   PubMed Web of Science ®Google Scholar
• WASMUTH JC, LA PORTE CJ, SCHNEIDER K, BURGER DM, ROCKSTROH JK: Comparison of two reduced-dose regimens of indinavir (600 mg versus 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). Antivir. Ther. (2004) 9(2):213-220.
   PubMed Web of Science ®Google Scholar
• LEE LS, PANCHALINGAM A, YAP MC, PATON NI: Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. (2004) 48(11):4476-4478.
   PubMed Web of Science ®Google Scholar
• KONOPNICKI D, DE WIT S, POLL B, CROMMENTUYN K, HUITEMA A, CLUMECK N: Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily. HIV Med. (2005) 6(1):1-6.
   PubMedGoogle Scholar
• RHAME FS, RAWLINS SL, PETRUSCHKE RA et al.: Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48(11):4200-4208.
   PubMed Web of Science ®Google Scholar
• MOOTSIKAPUN P, CHETCHOTISAKD P, ANUNNATSIRI S, BOONYAPRAWIT P: Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts < 200 cells/mm3: 96-week outcomes. Antivir. Ther. (2005) 10(8):911-916.
   PubMed Web of Science ®Google Scholar
• BOYD M, MOOTSIKAPUN P, BURGER D et al.: Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir. Ther. (2005) 10(2):301-307.
   PubMed Web of Science ®Google Scholar
• CRESSEY TR, LEENASIRIMAKUL P, JOURDAIN G et al.: Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J. Antimicrob. Chemother. (2005) 55(6):1041-1044.
   PubMed Web of Science ®Google Scholar
• JUSTESEN US, LEVRING AM, THOMSEN A, LINDBERG JA, PEDERSEN C, TAURIS P: Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up. HIV Med. (2003) 4(3):250-254.
   PubMedGoogle Scholar
• JOHNSON VA, BRUN-VEZINET F, CLOTET B, KURITZKES D, PILLAY D, SCHAPIRO JM, RICHMAN DD: Update of the drug resistance mutations in HIV-1: Fall 2006. Topics in HIV Medicine (2006) 14:125-130.
   PubMedGoogle Scholar
• ZALA C, ALEXANDER CS, OCHOA C et al.: Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir. J. Acquir. Immune Defic. Syndr. (2005) 38(3):363-364.
   Google Scholar
• MERCK & CO., INC.: Crixivan® (indinavir sulfate) capsules prescribing information. Merck & Co., Inc. Rahway (NJ) USA (1996).
   Google Scholar
• VAN HEESWIJK RP, VELDKAMP AI, HOETELMANS RM et al.: The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS (1999) 13(14):F95-F99.
   PubMed Web of Science ®Google Scholar